This study was reviewed and given approval by the North West Multi-centre Research Ethics Committee. Reference number MREC 02/8/79, Protocol number GS-02-1008c.
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors
Article first published online: 11 MAR 2009
© 2009 British HIV Association
Volume 10, Issue 6, pages 351–355, July 2009
How to Cite
Benn, P., Sauret-Jackson, V., Cartledge, J., Ruff, C., Sabin, C., Moyle, G., Linney, A., Reilly, G. and Edwards, S. (2009), Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Medicine, 10: 351–355. doi: 10.1111/j.1468-1293.2009.00694.x
This study was presented in part at the following conferences: 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13–16 November 2005, Dublin (Abstract 8); 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, 24–27July 2005, Rio de Janeiro, Brazil (Abstract TuLB2.3C02).
- Issue published online: 10 JUN 2009
- Article first published online: 11 MAR 2009
- Accepted 15 January 2009
- 3D surface laser scans;
- facial lipoatrophy;
- tenofovir DF;
Thymidine nucleoside reverse transcriptase inhibitors (NRTIs) are associated with subcutaneous fat loss. Facial changes cannot be assessed by dual-energy X-ray absorptiometry (DEXA) scans. There are limited objective data on the reversibility of facial lipoatrophy.
We performed a facial volume substudy of a randomized thymidine NRTI replacement study carried out in HIV-infected subjects with moderate to severe lipoatrophy. Facial volume changes were assessed using validated 3D laser imaging. Changes in body composition were measured using DEXA scans. The association between changes in facial volume and body composition parameters at 48 weeks was measured using Spearman's rank correlation.
Forty-seven individuals (46 male), 11 receiving zidovudine and 36 receiving stavudine, switched to either tenofovir disoproxil fumarate (DF) (n=23) or abacavir (ABC) (n=24). Thirty-nine of these 47 patients (84.8%) reported facial lipoatrophy at baseline. The median volume increase in both cheeks from baseline was 1857.3 mm3. These volume changes and increases in limb fat at 48 weeks were similar in the two groups and correlated significantly (Spearman's r=0.41, P=0.004).
Facial volume in lipoatrophic individuals was found to increase after thymidine NRTI replacement. We demonstrated a significant correlation between improvements in facial and limb fat parameters. Switching from thymidine NRTIs in patients with facial lipoatrophy could potentially reduce the need for cosmetic interventions.